Vitamin D Supplementation Can Shrink Uterine Fibroids
Vitamin D supplementation effectively reduces uterine fibroid size in women with vitamin D deficiency and should be considered as a safe, low-cost therapeutic option, particularly for those seeking fertility preservation or non-surgical management.
Evidence-Based Recommendation
The most recent and highest quality evidence demonstrates that vitamin D supplementation significantly decreases fibroid size. A 2025 pilot study showed that low-dose vitamin D (25,000 IU every 2 weeks for 6 months) reduced fibroid diameter from 56.9 mm to 52.2 mm (P = 0.001), while untreated controls experienced significant fibroid growth from 67.1 mm to 79.4 mm over the same period 1. Additionally, vitamin D reduced fibroid vascularity indices, suggesting decreased blood flow to the tumors 1.
A 2024 systematic review and meta-analysis of randomized controlled trials (511 participants) confirmed these findings, showing vitamin D supplementation significantly decreased fibroid size (SMD: -0.48,95% CI: -0.66, -0.31) with greater effects observed when treatment exceeded 8 weeks (SMD: -0.62,95% CI: -0.88, -0.37) 2.
Clinical Context and Mechanism
Importantly, the ACR Appropriateness Criteria for Management of Uterine Fibroids (2024) does not include vitamin D in its medical management recommendations 3. The guideline focuses on established first-line treatments (oral contraceptives, progestin IUDs, tranexamic acid) and second-line options (GnRH agonists/antagonists, progesterone receptor modulators). This represents a gap between emerging research evidence and current clinical guidelines.
However, the research evidence is compelling:
- Mechanism of action: Vitamin D exerts antiproliferative effects, reduces DNA damage in fibroid cells, and modulates estrogen and progesterone receptor expression 4
- Safety profile: No significant adverse effects reported across multiple trials 1, 5, 6
- Cost-effectiveness: Substantially less expensive than surgical or interventional procedures
Practical Implementation
Patient Selection
- Ideal candidates: Women with vitamin D deficiency (25[OH]D < 30 ng/mL) and uterine fibroids
- Particularly appropriate for: Those seeking fertility preservation, surgical candidates requiring preoperative size reduction, or patients preferring non-invasive management
Dosing Strategies
Based on the evidence:
- Low-dose regimen: 25,000 IU every 2 weeks for 6 months 1
- Alternative regimen: 1,600 IU daily for 3 months 7
- Higher-dose option: 50,000 IU weekly for 8 weeks 6
Expected Outcomes
- Fibroid size reduction: 4-8% decrease in diameter over 3-6 months
- Prevention of growth: Stabilization versus 5-6 mm growth in untreated patients
- Symptom improvement: Reduction in dysmenorrhea, heavy menstrual bleeding, and urinary frequency 7
- Recurrence prevention: 50% reduction in recurrence rates post-myomectomy 5
Important Caveats
- Treatment duration matters: Effects are more pronounced with supplementation >8 weeks 2
- Baseline vitamin D status: Benefits are most evident in women with documented deficiency
- Not a replacement for established therapies: Should be considered complementary to, not a substitute for, guideline-recommended treatments when rapid symptom control is needed
- Limited data on fibroid characteristics: Current evidence doesn't show differential effects based on fibroid number, size, or location 1, 8
Clinical Algorithm
Step 1: Check serum 25(OH)D level in women with uterine fibroids
Step 2: If deficient (<30 ng/mL), initiate vitamin D supplementation
Step 3: Choose dosing based on severity and patient preference
Step 4: Reassess fibroid size and symptoms at 3 and 6 months
Step 5: Continue supplementation if response observed; consider escalation to established medical therapies if inadequate response
Future Considerations
While vitamin D shows promise as documented in multiple RCTs 1, 2, 7, 5, 6, larger multicenter trials are needed before it will likely be incorporated into formal clinical practice guidelines. The 2026 systematic review emphasizes the need for standardized dosing protocols and definitive patient selection criteria 4. Until then, vitamin D represents a reasonable, evidence-based option for appropriately selected patients, particularly given its excellent safety profile and low cost.